NCT05977907View on ClinicalTrials.gov

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 14, 2023

Primary Completion Date

October 16, 2026

Study Completion Date

October 16, 2028

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab is an investigational drug in this study

DRUG

IO102-103

IO102-103 is an investigational drug in this study.

Trial Locations (5)

19107

NOT_YET_RECRUITING

Thomas Jefferson University Hospital, Philadelphia

20016

NOT_YET_RECRUITING

Sibley Memorial Hospital, Washington D.C.

21287

RECRUITING

Johns Hopkins University, Baltimore

60611

NOT_YET_RECRUITING

Northwestern Memorial Hospital, Chicago

97213

NOT_YET_RECRUITING

Providence Cancer Institute, Portland

Sponsors

Collaborators (1)

IO Biotech
All Listed Sponsors
collaborator

IO Biotech

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT05977907 - Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). | Biotech Hunter | Biotech Hunter